Core Insights - Tarsus Pharmaceuticals is advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, a significant eye disease with no FDA-approved therapy, with plans to initiate a Phase 2 study in the second half of 2025 [1][2][7] Company Updates - In 2024, Tarsus established XDEMVY as one of the most successful eye care launches, achieving consistent quarter-over-quarter revenue growth and broad payer coverage, with over 104,000 bottles delivered and more than $113 million in net product sales during the first nine months of 2024 [3][7] - The company plans to enhance its strategic initiatives in 2025, focusing on generating new evidence for XDEMVY and pursuing Ocular Rosacea as a transformative opportunity in eye care [3][6] - Tarsus has deployed approximately 50 new sales representatives in Q3 2024, which is expected to positively impact sales in Q4 2024 [7] Product Information - XDEMVY (lotilaner ophthalmic solution, 0.25%) is designed to treat Demodex blepharitis by targeting Demodex mite infestation, with pivotal trials showing significant improvements in key endpoints [10][14] - Ocular Rosacea affects approximately 15-18 million Americans, with TP-04 representing a potential category-creating therapy for this condition [7][12] - The company anticipates potential European regulatory approval for a preservative-free formulation of XDEMVY in 2027 and is working on regulatory pathways in Japan and China for its products [7][14]

Core Insights - Tarsus Pharmaceuticals is advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, a significant eye disease with no FDA-approved therapy, with plans to initiate a Phase 2 study in the second half of 2025 [1][6][11] Company Updates - Tarsus reported that 2024 was a groundbreaking year with XDEMVY achieving consistent quarter-over-quarter revenue growth, rapid physician adoption, and broad payer coverage, generating over $113 million in net product sales during the first nine months of 2024 [3][6] - The company delivered more than 104,000 bottles of XDEMVY to patients, with over 13,000 Eye Care Professionals prescribing it, and more than 70% of these professionals writing prescriptions for multiple patients [6] - Tarsus plans to enhance its strategic initiatives in 2025, focusing on generating new evidence for XDEMVY and pursuing Ocular Rosacea as a transformative opportunity in eye care [3][6] Product Information - XDEMVY (lotilaner ophthalmic solution, 0.25%) is designed to treat Demodex blepharitis by targeting Demodex mite infestation, with pivotal trials showing significant improvements in key endpoints [9][10] - TP-04 is an investigational formulation of lotilaner aimed at treating Ocular Rosacea, which affects approximately 15-18 million Americans, with a clear regulatory path established based on FDA feedback [6][11] Future Plans - The company is on track for potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027 and anticipates sharing results from a prevalence study in Japan in 2025 [14] - Tarsus is also developing TP-05, an oral systemic formulation of lotilaner, aimed at preventing Lyme disease transmission [12][13]

Core Viewpoint - Tarsus Pharmaceuticals, Inc. (TARS) shows potential for further upside, with a mean price target of $64 indicating a 27% upside from its current price of $50.40, following a 10.4% gain over the past four weeks [1]. Price Target Analysis - The average price target consists of eight estimates ranging from a low of $41 to a high of $84, with a standard deviation of $12.83, indicating variability among analysts [2]. - The lowest estimate suggests an 18.7% decline, while the highest indicates a 66.7% upside, highlighting the range of opinions among analysts [2]. Analyst Sentiment - Analysts exhibit strong agreement on TARS's ability to report better earnings than previously predicted, which supports the expectation of an upside [4]. - A positive trend in earnings estimate revisions has been shown to correlate with stock price movements, reinforcing the potential for TARS's stock to rise [9]. Earnings Estimates - Over the last 30 days, six earnings estimates for TARS have been revised upward, with no negative revisions, leading to a 13.4% increase in the Zacks Consensus Estimate [10]. - TARS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [11]. Conclusion on Price Targets - While the consensus price target may not be a reliable predictor of TARS's price movement, the direction implied by the targets appears to be a useful guide for investors [12].

Shares of Tarsus Pharmaceuticals, Inc. (TARS) have gained 22.4% over the past four weeks to close the last trading session at $44.83, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $63.25 indicates a potential upside of 41.1%.The average comprises eight short-term price targets ranging from a low of $41 to a high of $84, with a standard deviation of $13.65. While the lowest est ...

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32.22%. A quarter ago, it was expected that this company would post a loss of $0.98 per share when it actually produced a loss of $0.88, delivering a surprise of 10.20%.Over the last four quarters, the company ...

Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Di ...

The market expects Tarsus Pharmaceuticals, Inc. (TARS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the ...

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call ...

IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ Chief Medical Advisor ...

Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 20.6% gain over the past four weeks.The sudden soaring of the stock price can be attributed to positive investor expectations regarding the financial performance of Tarsus’ only marketed product in the United States, Xdemvy, approved for demodex blepharitis. The company i ...